In an era where inclusivity and diversity are at the forefront of social, economic, and scientific progress, it is imperative that the medical field also reflects the diverse patient populations it serves. Fortrea, a pioneering company in clinical research, has unveiled a groundbreaking solution to enhance diversity and inclusion in this domain. Leveraging real-world data, patient insights, and an innovative systematic approach, Fortrea aims to design, operationalize, and measure the effectiveness of diversity action plans in clinical trials. Simultaneously, the company is expanding its non-commercial specialty pharmacy, FortreaRx, to cater to increased patient access needs. These initiatives mark a significant milestone in Fortrea’s quest for a more inclusive and patient-centered healthcare system.
Enhancing Diversity and Inclusion in Clinical Research
Fortrea’s comprehensive approach to improving diversity and inclusion in clinical research taps into real-world data and patient insights. By harnessing the power of these resources, the company can identify and understand the barriers that deter individuals from diverse backgrounds from participating in clinical trials. With this understanding, Fortrea can then design targeted action plans that address these barriers effectively. Moreover, by implementing a systematic process, the company ensures that its action plans are fully operationalized and their impact is continuously measured. These measures will undoubtedly result in more representative and inclusive clinical trials, enabling healthcare professionals to make more informed decisions that benefit all patients.
FortreaRx: Expanding Patient Access
Recognizing the importance of patient access to life-changing medications, Fortrea has expanded its non-commercial specialty pharmacy, FortreaRx. This expansion aims to deliver flexible and scalable solutions to customers, ensuring that patients have direct access to the medications they require. By expanding its services, FortreaRx can better cater to the diverse needs of patients, including those from marginalized communities who may face additional barriers when accessing healthcare. With this expansion, Fortrea is not only prioritizing patient well-being but is also contributing towards reducing health disparities.
The Merger and The Future
In another significant development, Fortrea’s affiliate, Middlefield Limited, announced its intention to merge International Clean Power Dividend Fund (CLP) into Infrastructure Dividend Split Corp. (Infrastructure Split Corp.), a split share corporation. This move solidifies Fortrea’s commitment to making strides across various sectors that synergistically contribute to the betterment of healthcare. By expanding its reach into infrastructure development, Fortrea aims to bolster the overall healthcare system, ensuring that patients have access to cutting-edge facilities and services.
Conclusion:
Fortrea’s dedication to advancing diversity, inclusion, and patient access is commendable. Its innovative solution to improve clinical research through the strategic use of real-world data and patient insights holds tremendous promise in achieving more representative and effective healthcare practices. Additionally, the expansion of FortreaRx highlights the company’s unwavering commitment to ensuring that patients from all backgrounds have access to life-changing medications. As Fortrea continues to forge ahead in the pursuit of a more inclusive healthcare landscape, it sets an exemplary precedent for the entire medical industry to follow.
Comments